Published in Proc Natl Acad Sci U S A on July 11, 2011
Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis (SLAM-2) | NCT02737202
Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer (2012) 6.14
Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov (2012) 5.26
Autophagy in malignant transformation and cancer progression. EMBO J (2015) 2.67
TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell (2012) 2.22
Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis. Am J Respir Cell Mol Biol (2013) 2.06
Lymphangioleiomyomatosis - a wolf in sheep's clothing. J Clin Invest (2012) 1.87
Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy (2012) 1.86
The liver kinase B1 is a central regulator of T cell development, activation, and metabolism. J Immunol (2011) 1.62
mTOR: a pharmacologic target for autophagy regulation. J Clin Invest (2015) 1.61
When autophagy meets cancer through p62/SQSTM1. Am J Cancer Res (2012) 1.58
Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal (2012) 1.50
Autophagy in idiopathic pulmonary fibrosis. PLoS One (2012) 1.45
Emerging role of autophagy in kidney function, diseases and aging. Autophagy (2012) 1.43
Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition. PLoS One (2012) 1.37
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell (2013) 1.15
Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion. PLoS One (2012) 1.08
A REDD1/TXNIP pro-oxidant complex regulates ATG4B activity to control stress-induced autophagy and sustain exercise capacity. Nat Commun (2015) 1.04
Beclin orthologs: integrative hubs of cell signaling, membrane trafficking, and physiology. Trends Cell Biol (2015) 1.00
Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis. J Neurosci (2012) 0.97
Autophagy: an 'Achilles' heel of tumorigenesis in TSC and LAM. Autophagy (2011) 0.97
Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med (2014) 0.97
Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. J Exp Med (2014) 0.96
Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells. Cell Cycle (2013) 0.95
Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers. Cancer Discov (2014) 0.94
Cross-cancer profiling of molecular alterations within the human autophagy interaction network. Autophagy (2015) 0.94
p62/sequestosome-1 up-regulation promotes ABT-263-induced caspase-8 aggregation/activation on the autophagosome. J Biol Chem (2013) 0.93
Autophagy: a potential therapeutic target in lung diseases. Am J Physiol Lung Cell Mol Physiol (2013) 0.92
Sequestosome 1/p62 facilitates HER2-induced mammary tumorigenesis through multiple signaling pathways. Oncogene (2014) 0.91
Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1. Hum Mol Genet (2014) 0.90
Autophagy in kidney health and disease. Antioxid Redox Signal (2013) 0.90
Survival by self-destruction: a role for autophagy in the placenta? Placenta (2012) 0.90
Advances in Autophagy Regulatory Mechanisms. Cells (2016) 0.90
Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges. Am J Respir Cell Mol Biol (2012) 0.89
Regulation and functional significance of autophagy in respiratory cell biology and disease. Am J Respir Cell Mol Biol (2012) 0.89
Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol (2014) 0.88
Macrophage migration inhibitory factor deficiency augments doxorubicin-induced cardiomyopathy. J Am Heart Assoc (2013) 0.88
Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide. Mol Cancer Res (2013) 0.88
Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. J Clin Invest (2013) 0.88
Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations From the 2015 Strategic Planning Conference. Pediatr Neurol (2016) 0.87
Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells. Oncotarget (2014) 0.86
Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift. Mol Cancer Res (2014) 0.85
Metabolic reprogramming in polycystic kidney disease. Nat Med (2013) 0.84
Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM). Horm Cancer (2012) 0.83
Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress. Am J Physiol Renal Physiol (2012) 0.82
The neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis. Front Cell Dev Biol (2014) 0.82
Harnessing autophagy for adoptive T-cell therapy. Immunotherapy (2012) 0.81
Role of Apigenin in Cancer Prevention via the Induction of Apoptosis and Autophagy. J Cancer Prev (2016) 0.80
High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting. Mol Cancer Res (2014) 0.80
PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex. Sci Rep (2015) 0.79
Management of lymphangioleiomyomatosis. F1000Prime Rep (2014) 0.79
RNA-Seq and ChIP-Seq reveal SQSTM1/p62 as a key mediator of JunB suppression of NF-κB-dependent inflammation. J Invest Dermatol (2014) 0.79
Endoplasmic reticulum stress and cell death in mTORC1-overactive cells is induced by nelfinavir and enhanced by chloroquine. Mol Oncol (2014) 0.79
mTORC1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress. Cancer Res (2016) 0.79
SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis. Cancer Res (2014) 0.79
Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway. Sci Rep (2015) 0.79
Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to ΔPK oncolytic activity in melanoma. Gene Ther (2014) 0.79
Impaired Mitochondrial Dynamics and Mitophagy in Neuronal Models of Tuberous Sclerosis Complex. Cell Rep (2016) 0.79
Getting to the finish line with mTORC1-targeted therapy. J Clin Invest (2012) 0.78
Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol (2014) 0.78
Self-eating: friend or foe? The emerging role of autophagy in idiopathic pulmonary fibrosis. Biomed Res Int (2013) 0.78
p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA. Oncogene (2016) 0.77
Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy. Cell Cycle (2015) 0.77
Loss of TSC2 confers resistance to ceramide and nutrient deprivation. Oncogene (2013) 0.77
Targeted deletion of Tsc1 causes fatal cardiomyocyte hyperplasia independently of afterload. Cardiovasc Pathol (2014) 0.76
Effects of Combining Rapamycin and Resveratrol on Apoptosis and Growth of TSC2-Deficient Xenograft Tumors. Am J Respir Cell Mol Biol (2015) 0.76
Expression of Beclin Family Proteins Is Associated with Tumor Progression in Oral Cancer. PLoS One (2015) 0.75
Mourning Dr. Alfred G. Knudson: the two-hit hypothesis, tumor suppressor genes, and the tuberous sclerosis complex. Cancer Sci (2016) 0.75
Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation. Cancer Res (2017) 0.75
p62/SQSTM1 cooperates with hyperactive mTORC1 to regulate glutathione production, maintain mitochondrial integrity and promote tumorigenesis. Cancer Res (2017) 0.75
Sustained activation of mTORC1 in macrophages increases AMPKα-dependent autophagy to maintain cellular homeostasis. BMC Biochem (2016) 0.75
Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex. Oxid Med Cell Longev (2017) 0.75
Therapeutic Strategies for Treatment of Pulmonary Lymphangioleiomyomatosis (LAM). Expert Opin Orphan Drugs (2014) 0.75
Rapamycin reversal of VEGF-C-driven lymphatic anomalies in the respiratory tract. JCI Insight (2017) 0.75
Human pluripotent stem cell-derived TSC2-haploinsufficient smooth muscle cells recapitulate features of Lymphangioleiomyomatosis. Cancer Res (2017) 0.75
Importance of tuberin in carcinogenesis. Oncol Lett (2017) 0.75
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J (2000) 41.48
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Autophagy fights disease through cellular self-digestion. Nature (2008) 33.83
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
The role of autophagy during the early neonatal starvation period. Nature (2004) 22.40
TSC2 mediates cellular energy response to control cell growth and survival. Cell (2003) 20.21
p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol (2005) 18.23
Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest (2003) 16.67
Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A (2003) 15.59
Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol (2009) 13.89
The tuberous sclerosis complex. N Engl J Med (2006) 13.53
A protein conjugation system essential for autophagy. Nature (1998) 12.71
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell (2006) 11.79
Role of autophagy in cancer. Nat Rev Cancer (2007) 10.88
Autophagy suppresses tumorigenesis through elimination of p62. Cell (2009) 9.95
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med (2008) 9.64
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest (2007) 9.33
Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell (2009) 9.14
mTOR signaling at a glance. J Cell Sci (2009) 8.66
Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med (2010) 8.28
The role of autophagy in cancer development and response to therapy. Nat Rev Cancer (2005) 8.18
Autophagy and metabolism. Science (2010) 8.10
Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell (2010) 7.61
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev (2004) 7.51
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev (2011) 7.43
Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev (2007) 7.41
The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol (2010) 6.95
ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. J Biol Chem (2009) 6.34
Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature (2010) 6.26
The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell (2008) 4.48
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell (2007) 4.48
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol (2006) 4.24
An Atg1/Atg13 complex with multiple roles in TOR-mediated autophagy regulation. Mol Biol Cell (2009) 4.07
Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell (2010) 4.07
Tsc2(+/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J Clin Invest (1999) 3.38
ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci U S A (2010) 3.03
Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. Eur J Pharmacol (2009) 2.61
Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol (2003) 2.54
Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer (2005) 2.42
Activation of autophagy during cell death requires the engulfment receptor Draper. Nature (2010) 2.30
Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell (2004) 1.98
Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am J Pathol (1995) 1.61
Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol Cell Neurosci (2002) 1.47
Specific killing of Rb mutant cancer cells by inactivating TSC2. Cancer Cell (2010) 1.42
Rheb controls misfolded protein metabolism by inhibiting aggresome formation and autophagy. Proc Natl Acad Sci U S A (2009) 1.40
Effect of chloroquine on morphology of cytoplasmic granules in maturing human leukocytes--an ultrastructural study. J Clin Invest (1967) 1.32
Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol Cancer (2009) 1.16
Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J Transl Med (2010) 1.15
Cell cycle-regulated phosphorylation of hamartin, the product of the tuberous sclerosis complex 1 gene, by cyclin-dependent kinase 1/cyclin B. J Biol Chem (2003) 0.95
Sirolimus--challenging current perspectives. Ther Drug Monit (2006) 0.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Mitochondria, oxidants, and aging. Cell (2005) 16.11
Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med (2003) 13.84
The tuberous sclerosis complex. N Engl J Med (2006) 13.53
53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell (2010) 8.70
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. Genome Res (2009) 6.83
A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci U S A (2008) 6.53
Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest (2003) 6.04
SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem (2005) 5.93
Augmented Wnt signaling in a mammalian model of accelerated aging. Science (2007) 5.62
A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci U S A (2008) 5.48
Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med (2008) 5.15
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A (2002) 4.93
Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science (2002) 4.88
Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science (2004) 4.61
The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. J Biol Chem (2006) 4.28
Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem (2002) 4.19
Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol (2010) 4.01
Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nat Neurosci (2005) 4.00
Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med (2006) 3.81
Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases. Science (2003) 3.70
Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci (2008) 3.64
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 3.54
A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci (2007) 3.51
The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calcium uniporter. Nat Cell Biol (2013) 3.39
Redox-based regulation of signal transduction: principles, pitfalls, and promises. Free Radic Biol Med (2008) 3.38
Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures. Ann Neurol (2002) 3.37
Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell (2008) 3.32
Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev (2005) 3.25
mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell (2008) 3.06
Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab (2011) 2.91
Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol (2006) 2.85
Perivascular epithelioid cell neoplasms: pathology and pathogenesis. Hum Pathol (2009) 2.80
Rapid turnover of actin in dendritic spines and its regulation by activity. Nat Neurosci (2002) 2.78
Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. Cell Metab (2011) 2.73
mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest (2011) 2.72
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med (2013) 2.66
Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler Thromb Vasc Biol (2004) 2.65
Rac1 deletion in mouse neutrophils has selective effects on neutrophil functions. J Immunol (2003) 2.59
Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med (2002) 2.56
Atg7 modulates p53 activity to regulate cell cycle and survival during metabolic stress. Science (2012) 2.56
Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol (2003) 2.54
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest (2013) 2.50
mTORC1-dependent and -independent regulation of stem cell renewal, differentiation, and mobilization. Proc Natl Acad Sci U S A (2008) 2.48
Mitochondrial dysfunction and oxidative stress mediate the physiological impairment induced by the disruption of autophagy. Aging (Albany NY) (2009) 2.45
Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer (2005) 2.42
A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell (2009) 2.41
Tuberous sclerosis complex proteins control axon formation. Genes Dev (2008) 2.33
Filamin A (FLNA) is required for cell-cell contact in vascular development and cardiac morphogenesis. Proc Natl Acad Sci U S A (2006) 2.28
Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO J (2007) 2.27
Utilization of a whole genome SNP panel for efficient genetic mapping in the mouse. Genome Res (2006) 2.26
Redox-dependent transcriptional regulation. Circ Res (2005) 2.23
Genomewide linkage analysis of quantitative spirometric phenotypes in severe early-onset chronic obstructive pulmonary disease. Am J Hum Genet (2002) 2.23
TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell (2012) 2.22
Somatic LKB1 mutations promote cervical cancer progression. PLoS One (2009) 2.21
The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet (2004) 2.19
Metabolic regulation by the mitochondrial phosphatase PTPMT1 is required for hematopoietic stem cell differentiation. Cell Stem Cell (2013) 2.12
An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice. Nat Med (2008) 2.12
Endothelial progenitor cells. Annu Rev Med (2005) 2.11
Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med (2014) 2.09
Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet (2003) 2.09
Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis. Am J Respir Cell Mol Biol (2013) 2.06
Regulation of endothelial nitric oxide synthase and postnatal angiogenesis by Rac1. Circ Res (2008) 2.04
Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A (2006) 2.02
Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum Genet (2007) 1.94
Loss of Tsc1 or Tsc2 induces vascular endothelial growth factor production through mammalian target of rapamycin. Cancer Res (2003) 1.90
Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circ Cardiovasc Genet (2008) 1.89
Unusually mild tuberous sclerosis phenotype is associated with TSC2 R905Q mutation. Ann Neurol (2006) 1.87
Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest (2009) 1.80
Free radicals and senescence. Exp Cell Res (2008) 1.79
Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A (2009) 1.75
Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem (2004) 1.75
Regulation of autophagy by the p300 acetyltransferase. J Biol Chem (2009) 1.69
Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner. J Neurosci (2009) 1.67
Activation of the mTOR signaling pathway in renal clear cell carcinoma. J Urol (2007) 1.66
Single nucleotide polymorphisms in innate immunity genes: abundant variation and potential role in complex human disease. Immunol Rev (2002) 1.65
Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell Metab (2007) 1.63
Rac1-null mouse embryonic fibroblasts are motile and respond to platelet-derived growth factor. Mol Biol Cell (2006) 1.60
Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc Natl Acad Sci U S A (2011) 1.58
FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell (2010) 1.58
Oncogene-induced senescence results in marked metabolic and bioenergetic alterations. Cell Cycle (2012) 1.57
Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. Am J Pathol (2003) 1.57
Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression. Cell Rep (2013) 1.56
The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol (2012) 1.53
Mitochondrial metabolism modulates differentiation and teratoma formation capacity in mouse embryonic stem cells. J Biol Chem (2008) 1.52
Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol (2004) 1.52
Novel loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17 686 women: the Women's Genome Health Study. Circ Cardiovasc Genet (2009) 1.51
Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal (2012) 1.50
Mitochondrial signaling, TOR, and life span. Biol Chem (2006) 1.48
Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol (2006) 1.47
Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol Cell Neurosci (2002) 1.47
The mammalian longevity-associated gene product p66shc regulates mitochondrial metabolism. J Biol Chem (2006) 1.46
Retracted The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Nature (2012) 1.44